Meeting
2018 ASCO Annual Meeting
Differential elevation of TERT activity and sensitivity to temozolomide by type of TERT mutation in MGMT promoter-methylated glioblastoma.
Authors
Michael Weller
Department of Neurology, University Hospital Zurich, Zurich, Switzerland
Michael Weller , Alexandros Papachristodoulou , Bettina Hentschel , Dorothee Gramatzki , Joerg Felsberg , Markus Loeffler , Gabriele Schackert , Manfred Westphal , Joerg Tonn , Manuela Silginer , Andreas von Deimling , Torsten Pietsch , Guido Reifenberger , Patrick Roth
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Citation
J Clin Oncol 36, 2018 (suppl; abstr 2013)
DOI
10.1200/JCO.2018.36.15_suppl.2013
Abstract #
2013
Poster Bd #
171
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Bortezomib sensitization of recurrent glioblastoma with unmethylated MGMT promoter to temozolomide, a phase II study (NCT03643549).
First Author: Dorota Goplen
Poster
2020 ASCO Virtual Scientific Program
Phase III TRIDENT trial: Radiation and temozolomide +/- tumor treating fields in newly diagnosed glioblastoma.
First Author: Wenyin Shi
Poster
2020 ASCO Virtual Scientific Program
Clinical, radiologic & prognostic profile of IDH wild type diffuse astrocytic glioma with molecular features of glioblastoma.
First Author: Oluwatosin Akintola
Poster
2019 ASCO Annual Meeting
Stratified monotherapy approach according to MGMT methylation status in elderly patients with glioblastoma.
First Author: Mitsuaki Shirahata